Sleep Wake Disorders Clinical Trial
Official title:
Improving Memory for Sleep Treatment Content With Text Messages
Verified date | October 2019 |
Source | University of California, Berkeley |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A drop off in improvement over the months and years after treatment is common. One contributor may be poor memory for the contents of treatment. This study seeks to determine whether text messages containing reminders of the content of sessions will improve treatment outcomes.
Status | Completed |
Enrollment | 176 |
Est. completion date | December 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 18 Years |
Eligibility |
Inclusion Criteria: 1. Scoring within the lowest quartile of the Children's Morningness-Eveningness Preferences Scale (CMEP; 27 or lower) and a 7-day sleep diary showing a sleep onset time of of 10:40 pm or later for 10-13 year olds, 11 pm or later for 14-16 year olds, and 11:20 pm or later for 17-18 year olds at least 3 nights per week. Must have had the current pattern of late bedtimes for the last 3 months. 2. 'At risk' in one of the five health domains: emotional, behavioral, social, physical, and cognitive. Emotional risk will be operationalized as a score of 4 or above on any of the following items on the Child Depression Rating Scale: Difficulty Having Fun, Social Withdrawal, Irritability, Depressed Feelings, Excessive Weeping, or a T-score of 61 or above on the Multidimensional Anxiety Scale for Children (MASC), based on age group (10-11 years, 12-15 year, 16-19 years) using the MASC-10 Profile. Behavioral risk will be operationalized as a Sensation Seeking Scale score greater than 3.93 for males ages 10-13, greater than 3.19 for females 10-13, greater than 4.07 for males 14-18, or greater than 3.19 for females 14-18; taking ADHD medication or Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children (KSADs) diagnosis of ADHD; current alcohol or substance abuse; or past alcohol or substance dependence. Social and cognitive risk will be defined as "worse" than others the teen's age in one or more social behavior from Child Behavior Checklist (CBCL) Section VI or failing one or more academic class from CBCL Section VII, respectively. Physical risk will be operationalized as a Physical Health Questionnaire-15 score of 4 or above, six or more days of school absences, or a BMI above the 85th percentile for the participant's sex and age. 3. Age between 10 and 18 and living with a parent or guardian and and attending a class/job by 9am at least 3 days per week; 4. English language fluency; 5. Able and willing to give informed assent. Exclusion Criteria: 1. An active, progressive physical illness (e.g., cancer, respiratory disorder) or neurological degenerative disease directly related to the onset and course of the sleep disturbance; 2. Evidence from clinical diagnosis or report by youth or parent of sleep apnea, restless legs or periodic limb movements during sleep. Youth presenting with provisional diagnoses of any of these disorders (e.g., sleep apnea) will be referred for a non-study polysomnography (PSG) evaluation at the parent's discretion and will be enrolled only if the diagnosis is disconfirmed; 3. Mental retardation, autism spectrum disorder, or other significantly impairing pervasive developmental disorder. Based on previous recruitment experiences in a youth depression study, it is expected that this exclusion will be invoked very infrequently (once every few years); 4. Bipolar disorder or schizophrenia or another current Axis I disorder if there is a significant risk of harm and/or decompensation if treatment of that comorbid condition is delayed as a function of participating in any stage of this study. Otherwise, all other comorbid psychiatric conditions will be allowed to (i) to maximize representativeness and (ii) because a byproduct may be that the treatment constitutes a helpful 'transdiagnostic' treatment for youth across psychiatric disorders. 5. A medication-free group may be difficult to recruit and would likely be unrepresentative. Hence, participants will not be excluded on the basis of stable use of medications (> 4 weeks). The exception was use of hypnotics and other medications known to alter sleep (e.g., melatonin). 6. History of substance dependence in the past six months; 7. Current suicide risk sufficient to preclude treatment on an outpatient basis. |
Country | Name | City | State |
---|---|---|---|
United States | University of California, Berkeley | Berkeley | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Berkeley |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Useful and Utilized Questionnaire | 6mo UUQ | Measured at 6-months post-treatment | |
Other | Useful and Utilized Questionnaire | 12mo UUQ | Measured at 12-months post-treatment | |
Other | Daily Sleep Diary | total sleep time (weekend nights), weeknight bedtime, weekend risetime, total wake time (SOL+WASO) weeknights, total wake time (SOL+WASO) weekend nights, naps. | Measured at 6-months post-treatment | |
Other | Daily Sleep Diary | total sleep time (weekend nights), weeknight bedtime, weekend risetime, total wake time (SOL+WASO) weeknights, total wake time (SOL+WASO) weekend nights, naps. | Measured at 12-months post-treatment | |
Primary | Total sleep time (TST) average on weeknights via Daily Sleep Diary | 6mo TST | Measured at 6-months post-treatment | |
Primary | Total sleep time (TST) average on weeknights via Daily Sleep Diary | 12mo TST | Measured at 12-months post-treatment | |
Primary | Average bedtime on weeknights measured via Daily Sleep Diary | 6mo Avg Bedtime | Measured at 6-months post-treatment | |
Primary | Average bedtime on weeknights measured via Daily Sleep Diary | 12mo Avg Bedtime | Measured at 12-months post-treatment | |
Primary | Morning Eveningness preference measured via Childrens Morningness Eveningness Preference Scale | 6mo CME | Measured at 6-months post-treatment | |
Primary | Morning Eveningness preference measured via Childrens Morningness Eveningness Preference Scale | 12mo CME | Measured at 12-months post-treatment | |
Primary | Patient Recall of Session Contents | 6-12mo Change in Patient Recall | Change from 6-months post-treatment to 12-months post-treatment | |
Secondary | Sleepiness scale | Embedded within the School Sleep Habits Survey | Measured at 6-months post-treatment | |
Secondary | Sleepiness scale | Embedded within the School Sleep Habits Survey | Measured at 12-months post-treatment | |
Secondary | Pittsburgh Sleep Quality Index | 6mo PSQI | Measured at 6-months post-treatment | |
Secondary | Pittsburgh Sleep Quality Index | 12mo PSQI | Measured at 12-months post-treatment | |
Secondary | Discrepancy between weeknights and weekends for Total Sleep Time, Bedtime, and Waketime via Daily Sleep Diary | 6mo Weeknight-Weekend Differences | Measured at 6-months post-treatment | |
Secondary | Discrepancy between weeknights and weekends for Total Sleep Time, Bedtime, and Waketime via Daily Sleep Diary | 12mo Weeknight-Weekend Differences | Measured at 12-months post-treatment | |
Secondary | Text Message Evaluation | Measure of the acceptability of receiving text messages | Measured at 12-months post-treatment | |
Secondary | Child Behavior Checklist | Parent measure | Measured at 6-months post-treatment | |
Secondary | Child Behavior Checklist | Parent measure | Measured at 12-months post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03852966 -
Better Sleep in Psychiatric Care - ADHD Pilot Study
|
N/A | |
Completed |
NCT04990206 -
Improving Sleep Health in Adults With Overweight or Obesity
|
N/A | |
Recruiting |
NCT06242717 -
Postpartum Screening for Anxiety and Comorbid Conditions
|
||
Completed |
NCT04200495 -
PSG Validation Study of Zensorium Biosensing Wearable Device
|
||
Recruiting |
NCT04690504 -
Validation of Circadian Biomarkers in Patients With Sleep Disorders
|
||
Recruiting |
NCT04729478 -
Comparison Between Natural Sleep Endoscopy and Drug-induced Sleep Endoscopy in Patients With Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT05012605 -
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
|
||
Completed |
NCT04451668 -
An Open Label Study of FT218 in Subjects With Narcolepsy
|
Phase 3 | |
Recruiting |
NCT03956745 -
Biomarkers for Circadian Timing in Healthy Adults
|
||
Completed |
NCT06440226 -
Testing Methods to Increase the Frequency of Lucid Dreaming
|
||
Recruiting |
NCT05971212 -
Sleep Support for Children With Neurodevelopmental Disorders
|
N/A | |
Withdrawn |
NCT04506112 -
Optimizing Cardiac Rehabilitation by Integrating Sleep Therapeutics
|
N/A | |
Completed |
NCT03130803 -
Biomarkers of Insufficient Sleep and Sleepiness
|
N/A | |
Recruiting |
NCT05565833 -
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
|
Phase 2 | |
Recruiting |
NCT04652882 -
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
|
Phase 3 | |
Recruiting |
NCT04214184 -
Biomarkers of Increased Free Living Sleep Time
|
N/A | |
Active, not recruiting |
NCT03617497 -
Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease
|
N/A | |
Completed |
NCT03576664 -
Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans
|
Early Phase 1 | |
Completed |
NCT02922439 -
Health Literacy Assessment and Intervention to Reduce Disparities: FLIGHT/VIDAS II
|
N/A | |
Completed |
NCT05568381 -
Sleep Disturbance in MCI: A Study of a Cognitive Behavioural Therapy Digital Intervention
|
N/A |